Paradigm Announces Enhancement to PCDx Cancer Testing Service

Addition of Protein Biomarkers, Including Key Immune Targets PD-L1 and PD1, Further Augments Tests Ability to Personalize Cancer Therapy

News provided by

Paradigm

Feb 03, 2015, 08:30 ET

PHOENIX and ANN ARBOR, Mich., Feb. 3, 2015 /PRNewswire-USNewswire/ -- Paradigm today announced an expansion to their Next Generation Paradigm Cancer Diagnostic (PCDx) service with the addition of key protein biomarkers analyzed by immunohistochemistry (IHC). This enhancement will include the addition of up to 21 IHCs linked to either oncologic therapies or targeted clinical trials increasing the number of actionable drug targets to 65 which is the largest number commercially available.

Paradigm Logo

Of the 21 IHCs, 15 will be available immediately and include: PD1, PD-L1, MGMT, MET, TOP1, PTEN, AR, CAIX, ER, HER2, IDO, PR, TRKA, TRKB and TUBB3.

The addition of other key targets including hENT1, TS, CTLA4, TLE3, LAG3 and TP is scheduled in a few weeks.

"The focus of our company and PCDx offering is to capture novel insight into molecular pathways from DNA, RNA to protein to accelerate molecular medicine and improve patient care" said Robert J. Penny MD, PhD, CEO of Paradigm. "Our ability to interrogate not only DNA and RNA, but now protein enables us to provide associations to over 65 oncology therapies and clinical trials. Paradigm's ability to provide clinical-grade next-generation sequencing (NGS) at >5000x coverage, coupled with key IHC analysis, all within 4-5 business days sets a new industry standard."

With this expansion, the Paradigm PCDx test now provides the ability to interrogate DNA mutations, chromosomal changes, mRNA expression, Copy Number Variations and Protein Expression. Currently, Paradigm is the only organization with the ability to interrogate mRNA targets by NGS in formalin fixed paraffin sections along with the other genomic markers.

About PARADIGM

Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit www.paradigmdx.org.

Logo - http://photos.prnewswire.com/prnh/20140819/137529

SOURCE Paradigm